Gefitinib and a second generation antisense targeting Mdm2 synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer
MELISI, Davide;TORTORA, GIAMPAOLO
2003-01-01
Abstract
Gefitinib and a second generation antisense targeting Mdm2 synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
